Kyverna therapeutics provides business update and reports full year 2023 financial results

Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology strong balance sheet, bolstered by recent public offering, expected to fund operations into 2026 emeryville, calif. , march 26, 2024 /prnewswire/ -- kyverna therapeutics, inc. (nasdaq: kytx), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the full year ended december 31, 2023.
KYTX Ratings Summary
KYTX Quant Ranking